Pages that link to "Q33374368"
Jump to navigation
Jump to search
The following pages link to Renal failure in multiple myeloma: incidence, correlations, and prognostic significance (Q33374368):
Displaying 50 items.
- Current Trends of Renal Impairment in Multiple Myeloma (Q26740444) (← links)
- The Prevalence and Management of Multiple Myeloma-Induced Kidney Disease in China (Q26740446) (← links)
- Defining the role of renal transplantation in the modern management of multiple myeloma and other plasma cell dyscrasias (Q26861037) (← links)
- The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function (Q33390284) (← links)
- Bortezomib in patients with renal impairment (Q33396250) (← links)
- Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens (Q33398587) (← links)
- Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment (Q33421008) (← links)
- Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment (Q33426615) (← links)
- Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV). (Q33442039) (← links)
- Pathogenesis of renal failure in multiple myeloma: any role of contrast media? (Q33616884) (← links)
- Pathogenesis and treatment of renal failure in multiple myeloma (Q34592826) (← links)
- Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma. (Q35603608) (← links)
- Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score (Q35664302) (← links)
- Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production (Q35664315) (← links)
- The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study (Q35832484) (← links)
- Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies (Q36196981) (← links)
- Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma (Q36444477) (← links)
- Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed Or Relapsed and Refractory Multiple Myeloma (Q36848015) (← links)
- Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration (Q37112901) (← links)
- Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance (Q37149205) (← links)
- Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer (Q37514088) (← links)
- Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study (Q37609489) (← links)
- The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma. (Q37665665) (← links)
- Tumor Cell-Derived Microvesicles Induced Not Epithelial-Mesenchymal Transition but Apoptosis in Human Proximal Tubular (HK-2) Cells: Implications for Renal Impairment in Multiple Myeloma (Q37729049) (← links)
- Management of hematological malignancies in patients affected by renal failure (Q37854710) (← links)
- Supportive Therapy in Multiple Myeloma (Q37867574) (← links)
- Guidelines for the diagnosis and management of multiple myeloma 2011 (Q37875193) (← links)
- Diagnosis and therapy of multiple myeloma (Q38107482) (← links)
- Current treatments for renal failure due to multiple myeloma (Q38109235) (← links)
- Is high cut-off hemodialysis effective in myeloma kidney? (Q38199171) (← links)
- Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment (Q38466621) (← links)
- Nuances in the Management of Older People With Multiple Myeloma (Q38796491) (← links)
- Pomalidomide in the treatment of relapsed multiple myeloma (Q39388200) (← links)
- Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment (Q40718791) (← links)
- Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. (Q40960198) (← links)
- Multiple myeloma: a case of atypical presentation on protein electrophoresis (Q41544685) (← links)
- Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. (Q42573839) (← links)
- Renal Insufficiency and Failure (Q42757287) (← links)
- Renal impairment in multiple myeloma: presenting features in different departments (Q44355194) (← links)
- Prognostic Risk Factor Evaluation in Patients With Relapsed or Refractory Multiple Myeloma Receiving Lenalidomide Treatment: Analysis of Renal Function by eGFR and of Additional Comorbidities by Comorbidity Appraisal (Q44477099) (← links)
- Screening and Differential Diagnosis of Renal Light Chain-Associated Diseases (Q45171913) (← links)
- The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EP (Q45787936) (← links)
- Results of a Multicenter Open-Label Randomized Trial Evaluating Infusion Duration of Zoledronic Acid in Multiple Myeloma Patients (the ZMAX Trial) (Q46029540) (← links)
- Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy (Q47162496) (← links)
- Stem cell mobilization in patients with dialysis-dependent multiple myeloma: Report of the Polish Myeloma Study Group. (Q47967442) (← links)
- Role of Plasmapheresis in the Management of Acute Kidney Injury in Patients With Multiple Myeloma: Should We Abandon It? (Q48119569) (← links)
- Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report (Q49199576) (← links)
- Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study (Q50089740) (← links)
- Evaluation of multiple myeloma patients presenting with renal failure in a university hospital in the year 2010. (Q50973983) (← links)
- Multiple myeloma and kidney disease. (Q54518612) (← links)